The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | An overview of the CAR agents in development in large cell lymphoma
David Maloney, BSc, MD, PhD, of the Fred Hutchinson Cancer Research Center, Seattle, WA gives an overview of the three agents in large cell lymphoma in the CAR field. The first, Axicabtagene Ciloleucel, is an approved drug for patients diffuse B cell or aggressive lymphoma. The second agent is the Novartis product Tisagenlecleucel and the third, the JUNO transcend data with the separated CD4 CD38 products. All three products have shown very encouraging response rates. Prof. Maloney explains that soon these three products will be available in the clinic and factors must be considered when selecting which one to use. These are the durability of the remission rate, the response rate, the safety profile and the cost.
